Estrogen receptor binding to estrogen response elements slows ligand dissociation and synergistically activates reporter gene expression.
Estradiol (E2)-liganded estrogen receptor (ER) bound to three or four tandem copies of a consensus ERE (EREc38) in a cooperative manner. E2-ER binding to one or two EREs was non-cooperative. When ER was liganded by the antiestrogen 4-hydroxytamoxifen (4-OHT), ER-ERE binding was not cooperative, regardless of the number of EREs. Here we evaluated how binding to EREc38 affects ER conformation in the ligand binding domain (LBD) as reflected in the dissociation kinetics of [3H]ligand from the ER. Binding of ER to EREc38 slowed the rate of dissociation of either E2 or 4-OHT, indicating that DNA allosterically modulates the LBD conformation creating a tighter fit between the ligand and the ER. Conformational differences in ER induced by E2 versus antiestrogen were not reflected in differences in E2 or 4-OHT dissociation parameters under these conditions. No difference in the association rate of E2- versus 4-OHT-liganded ER binding to EREc38 was detected in electrophoretic mobility shift assay (EMSA). Synergistic, E2-dependent activation of a reporter gene was detected from three and four, but not one or two, tandem copies of EREc38. These observations suggest that cooperative binding of E2-ER to multiple copies of EREc38 is likely responsible for transcriptional synergy and that cooperativity may not involve direct interaction between the LBDs of ERE-bound ER. Since the number of copies of EREc38 did not alter E2 dissociation kinetics, functional synergy must involve cellular factors in addition to the ER ligand.
Klinge
C M
CM
Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine, KY 40292, USA. carolyn.klinge@louisville.edu
D000818:Animals; D002417:Cattle; D004965:Estrogen Antagonists / Q000494:pharmacology; D005260:Female; D017930:Genes, Reporter; D006801:Humans; D008024:Ligands; D009687:Nuclear Proteins / Q000502:physiology*; D011960:Receptors, Estrogen / Q000819:agonists / Q000737:chemistry / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000494:pharmacology; D015533:Transcriptional Activation / Q000502:physiology*; D014407:Tumor Cells, Cultured
D004965:Estrogen Antagonists; D008024:Ligands; D009687:Nuclear Proteins; D011960:Receptors, Estrogen; D013629:Tamoxifen; C016601:afimoxifene